title: Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy.
abstract: hLpL(GPI) transgenic mice that overexpress human lipoprotein lipase (hLpL) with a glycosylphosphatidylinositol anchor on cardiomyocytes develop lipotoxic cardiomyopathy associated with increased cardiac uptake of plasma lipids. We hypothesized that peroxisome proliferator-activated receptor (PPAR)alpha, PPARgamma, or a PPARalpha/gamma agonist would alter cardiac function by modulating lipid uptake by the heart. hLpL(GPI) mice were administered rosiglitazone (10 mg/kg/day), fenofibrate (100 mg/kg/day), or DRF2655, an alkoxy propanoic acid analog (10 mg/kg/day), for 16 days. Rosiglitazone reduced plasma triglyceride (TG) from 107.63 +/- 6.98 to 77.61 +/- 3.98 mg/dl, whereas fenofibrate had no effect. DRF2655 reduced TG to 33.17 +/- 4.12 mg/dl. Rosiglitazone and DRF2655 decreased heart TG and total cholesterol; fenofibrate had no effect. Molecular markers for cardiac dysfunction, atrial natriuretic factor, brain natriuretic peptide, and tumor necrosis factor-alpha were decreased with rosiglitazone and increased with fenofibrate. Echocardiographic measurements showed reduced fractional shortening and increased left ventricular systolic dimension with fenofibrate. No changes in these parameters were observed with rosiglitazone or DRF2655 treatment. Muscle-specific carnitine palmitoyltransferase-1 and fatty acid transporter protein-1 gene expression were increased with fenofibrate and DRF2655 treatment; no change in expression of these genes was noted with rosiglitazone treatment. Rosiglitazone and DRF2655 reduced TG uptake by the heart, and fenofibrate treatment increased fatty acid uptake. Thus, in a lipotoxic cardiomyopathy mouse model, a PPARgamma agonist reduced cardiac lipid and markers of cardiomyopathy, whereas an agonist of PPARalpha did not improve cardiac lipids and worsened heart function. These changes were paralleled by alterations in heart lipid uptake. Overall, PPAR activators exhibit differential effects in this model of lipotoxic dilated cardiomyopathy.
authors.affiliation: Department of Medicine, Columbia University, New York, NY 10032, USA.
authors.forename: Reeba K
authors.initials: RK
authors.lastname: Vikramadithyan
authors.forename: Kumiko
authors.initials: K
authors.lastname: Hirata
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yagyu
authors.forename: Yunying
authors.initials: Y
authors.lastname: Hu
authors.forename: Ayanna
authors.initials: A
authors.lastname: Augustus
authors.forename: Shunichi
authors.initials: S
authors.lastname: Homma
authors.forename: Ira J
authors.initials: IJ
authors.lastname: Goldberg
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008071:Lipoprotein Lipase / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D010078:Oxazines / Q000494:pharmacology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000097:blood / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology*
chemical_list: C476557:DRF 2655; D010078:Oxazines; D047492:Peroxisome Proliferator-Activated Receptors; D011422:Propionates; D008071:Lipoprotein Lipase